Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

Journal of Crohn's and Colitis

Volumn 6, Issue 2, 2012, Pages 143-153

  Sprakes, Michael B ^a   Ford, Alexander C ^a   Warren, Lisa ^a   Greer, Dan ^a   Hamlin, John ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Crohn's disease; Infliximab; Sustained clinical benefit; Tolerability

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CHICKENPOX; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; HYPERSENSITIVITY; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE RESECTION; LUNG TUBERCULOSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT INFECTION; REMISSION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SKIN ABSCESS; TREATMENT DURATION; TREATMENT RESPONSE; WHEEZING;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MULTIVARIATE ANALYSIS; PHENOTYPE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856701574     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.07.011     Document Type: Article

References (26)

1. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
2. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., van Deventer S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Hanauer S.B. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
5. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., Van Steen K., Vermeire S., Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
6. Sprakes M.B., Ford A.C., Suares N.C., Warren L., Greer D., Donnellan C.F., Jennings J.S., Everett S.M., Hamlin P.J. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther 2010, 32:1357-1363.
7. Waugh A.W., Garg S., Matic K., Gramlich L., Wong C., Sadowski D.C., Millan M., Bailey R., Todoruk D., Cherry R., Teshima C.W., Dieleman L., Fedorak R.N. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010, 32:1129-1134.
8. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., Van Steen K., Vermeire S., Rutgeerts P. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
9. O'Donnell S., Murphy S., Anwar M., O'Sullivan M., Breslin N., O'Connor H.J., Ryan B.M., O'Morain C.A. Safety of infliximab in 10 years of clinical practice. Eur J Gastroenterol Hepatol 2011, 23:603-606.
10. Zabana Y., Domenech E., Manosa M., Garcia-Planella E., Bernal I., Cabré E., Gassull M.A. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9 year experience in clinical practice. Aliment Pharmacol Ther 2010, 31:553-560.
11. Caspersen S., Elkjaer M., Riis L., Pedersen N., Mortensen C., Jess T., Sarto P., Hansen T.S., Wewer V., Bendtsen F., Moesgaard F., Munkholm P. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008, 6:1212-1217.
12. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R.H., Broussard D.L., Tang K.L., van der Woude C.J., Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
13. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., Caprilli R., Colombel J.F., Gasche C., Geboes K., Jewell D.P., Karban A., Loftus E.V., Peña A.S., Riddell R.H., Sachar D.B., Schreiber S., Steinhart A.H., Targan S.R., Vermeire S., Warren B.F. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
14. Long M.D., Drossman D.A. Inflammatory bowel disease, irritable bowel syndrome or what? A challenge to the functional-organic dichotomy. Am J Gastroenterol 2010, 105:1796-1798.
15. Drossman D.A., Whitehead W.E., Camilleri M. Irritable bowel syndrome: A technical review for practice guideline development. Gastroenterology 1997, 112:2120-2137.
16. Chang L., Toner B.B., Fukudo S., Guthrie E., Locke G.R., Norton N.J., Sperber A.D. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006, 130:1435-1446.
17. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., Ternant D., Watier H., Paintaud G., Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomised trial. Gastroenterology 2008, 134:1861-1868.
18. Ochenrider M.G., Patterson D.J., Aboulafia D.M. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010, 10:144-148.
19. Chaparro M., Panes J., Garcia V., Mañosa M., Esteve M., Merino O., Andreu M., Gutierrez A., Gomollón F., Cabriada J.L., Montoro M.A., Mendoza J.L., Nos P., Gisbert J.P. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose escalation in patients losing response. J Clin Gastroenterol 2011, 45:113-118.
20. Gonzaga J.E., Ananthakrishnan A.N., Issa M., Beaulieu D.B., Skaros S., Zadvornova Y., Johnson K., Otterson M.F., Binion D.G. Durability of infliximab in Crohn's disease: A single-center experience. Inflamm Bowel Dis 2009, 15:1837-1843.
21. Teshima C.W., Thompson A., Dhanoa L., Dieleman L.A., Fedorak R.N. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009, 23:348-352.
22. Rudolph S.J., Weinberg D.I., McCabe R.P. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008, 53:1033-1041.
23. Caviglia R., Ribolsi M., Rizzi, Emerenziani S., Annunziata M.L., Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007, 21:5238-5244.
24. Poupardin C., Lemann M., Gendre J.P., Sabaté J.M., Marteau P., Chaussade S., Delchier J.C., Bouhnik Y., Chaput J.C., Poupon R., Soulé J.C., Benhamou Y., Grangé J.D., Coffin B. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicentre study with a 15-month follow-up. Gastroenterol Clin Biol 2006, 30:247-252.
25. National Institute for Health and Clinical Excellence guidance Accessed February 2011. http://guidance.nice.org.uk/TA187.
26. Louis E., Vernier-Massouille, Grimaud J.-C., Bouhnik Y., Laharie D., Dupas J., Pillant H., Picon L., Veyrac M., Flamant M., Savoye G., DeVos M., Jian R., Paintaud G., Piver E., Colombel J., Mary J., Lémann M. Infliximab discontinuation in Crohn's disease patients in stable remission on combined immunosuppressors: a prospective ongoing cohort study. Gut 2008, 57(Suppl. 2). A-66.